AsianScientist (Sep. 10, 2015) – The National Cancer Center Singapore (NCCS) and A*STAR’s Institute of Molecular and Cell Biology (IMCB) have entered into a partnership to enable closer collaboration and networking among researchers from the two institutions. This move will benefit both parties through the sharing of knowledge among the scientists. The ultimate aim is to develop new therapeutic treatments for cancer patients.
Under this collaboration, four principal investigators (PIs) from each institution will hold joint appointments at the respective institutions. These PIs each have outstanding expertise in different areas of oncology research ranging from developmental biology to cancer genomics.
IMCB focuses on discovery and translational research on human diseases to further understand the diseases and design therapeutic strategies against them. In the area of cancer, IMCB has been conducting cutting edge research in cancer genetics and therapeutics. At NCCS, its researchers and clinician scientists conduct basic research in medical sciences and clinical trials besides dealing with translational research.
“This collaboration will enhance translational research, where our scientists can further share resources and exchange knowledge from the basic sciences into the development of new treatments, as well as to translate the findings from clinical trials into everyday practice,” said Professor Soo Khee Chee, NCCS Director.
Professor Hong Wanjin, Executive Director, IMCB said, “ With IMCB’s deep capabilities in human biology and oncology research, and the strong clinical expertise at NCCS, I am confident that the collaboration will yield breakthroughs that can be translated into novel, effective therapeutics to address unmet medical need for cancer.”
Source: A*STAR; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.